Their pain drug treats neuopathic pain. Ground breaking mid-2006...

Their pain drug treats neuopathic pain. Ground breaking mid-2006 research in the States identifies where in the nervous system, and how this pain comes about (following nerve related damage or injury).

ACV1 first developed several years ago, specifically acts to desensitise pain sensing nerves......exactly to compliment the findings of the University of Utah research. (search it all for yourself)

In other words, ACV1 works exactly in the part of the nervous system where these USA scientists suggest it should. In fact the USA research confirms that ACV1 is likely to not only work....but to probably accelerate recovery of these injured nerves.

In laboratory animals, ACV1 has profound, direct effects on pain sensing nerves in the peripheral nervous system called C-fibres, which are hypersensitive in neuropathic pain. It blocks a subtype of a broad class of receptors called neuronal nicotinic acetylcholine receptors (nAChR) which reside on the C-fibres. ACV1 has been shown to directly reduce the sensitivity of sensitised C-fibres. It is the first drug to utilise this biochemical mechanism.

No other pain drug targets the exact and precise location or source of the pain, as that of ACV1.

Its early day, but there is a good chance that MBP can get most of this $5 billion market and catapult the share price value to more than $5 over time. Share price now is 14 cents.